Brazil's Anvisa orders recall of Paramol batch and seizes counterfeit Mounjaro

Claims

What the coverage asserts, and how well corroborated each claim is across sources.

• [● 19 SOURCES] Mounjaro is a tirzepatide‑based GLP‑1 agonist used for diabetes and weight‑loss treatment. (In all belongs‑true articles)
• [● 19 SOURCES] Consumers are urged to obtain medicines only from regulated pharmacies, keep invoices and verify packaging. (All belongs‑true articles)
• [● 10 SOURCES] The recall applies nationwide across Brazil. (Anvisa)
• [DISPUTED] Anvisa ordered the seizure of a falsified batch of the medication Mounjaro on 30 July 2026. (Anvisa)
• [● 19 SOURCES] Manufacturer Eli Lilly do Brasil discovered the incompatibility and reported it to Anvisa. (All belongs‑true articles)
• [● 19 SOURCES] The affected batch is identified by lot number D881474 and serial number 302199651396. (All belongs‑true articles)
• [● 18 SOURCES] Anvisa advises that the product must not be distributed, sold, or used. (Anvisa)
• [● 19 SOURCES] Use of the falsified product could cause serious therapeutic failure or unpredictable adverse reactions. (All belongs‑true articles)
• [DISPUTED] Anvisa ordered the seizure of a falsified Mounjaro batch on 30 July 2026. (All belongs‑true articles)
• [● 18 SOURCES] Mounjaro's active ingredient is tirzepatide, a GLP‑1 receptor agonist. (Drug information)
• [● 10 SOURCES] The seizure aims to prevent health risks from the unknown composition of the falsified medication.
• [● 10 SOURCES] The affected lot is D881474 and the serial number 302199651396, which indicates falsification.